GRI Bio Inc. Common Stock (NASDAQ: GRI)
$1.78
+0.0800 ( +4.71% ) 94.1K
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Market Data
Open
$1.78
Previous close
$1.70
Volume
94.1K
Market cap
$1.04M
Day range
$1.70 - $1.86
52 week range
$1.46 - $370.37
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
pre | Proxies and info statements | 4 | Apr 29, 2024 |
8-k | 8K-related | 17 | Apr 01, 2024 |
10-k | Annual reports | 106 | Mar 28, 2024 |
8-k | 8K-related | 22 | Feb 02, 2024 |
8-k | 8K-related | 19 | Jan 30, 2024 |
8-k | 8K-related | 14 | Jan 19, 2024 |
8-k | 8K-related | 43 | Jan 16, 2024 |
8-k | 8K-related | 14 | Jan 08, 2024 |
def | Proxies and info statements | 4 | Jan 02, 2024 |
pre | Proxies and info statements | 4 | Dec 20, 2023 |